Ernexa Therapeutics, Inc. (ERNA)
1.36
-0.27
(-16.56%)
USD |
NASDAQ |
Nov 20, 16:00
1.41
+0.05
(+3.68%)
After-Hours: 20:00
Ernexa Therapeutics Enterprise Value : -3.028M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -3.028M |
| November 19, 2026 | -2.584M |
| November 18, 2026 | -2.600M |
| November 17, 2026 | -2.584M |
| November 16, 2026 | -2.485M |
| November 13, 2026 | -2.501M |
| November 12, 2026 | -2.320M |
| November 11, 2026 | -2.090M |
| November 10, 2026 | -1.959M |
| November 09, 2026 | -1.893M |
| November 06, 2026 | -2.172M |
| November 05, 2026 | -2.255M |
| November 04, 2026 | -1.991M |
| November 03, 2026 | -1.942M |
| November 02, 2026 | -2.057M |
| October 30, 2026 | -2.024M |
| October 29, 2026 | -1.794M |
| October 28, 2026 | -2.008M |
| October 27, 2026 | -1.986M |
| October 26, 2026 | -2.077M |
| October 23, 2026 | -1.868M |
| October 22, 2026 | -1.852M |
| October 21, 2026 | -1.794M |
| October 20, 2026 | -1.580M |
| October 19, 2026 | -2.008M |
| Date | Value |
|---|---|
| October 16, 2026 | -1.827M |
| October 15, 2026 | -1.695M |
| October 14, 2026 | -1.794M |
| October 13, 2026 | -1.630M |
| October 12, 2026 | -1.630M |
| October 09, 2026 | -1.317M |
| October 08, 2026 | -1.169M |
| October 07, 2026 | -1.333M |
| October 06, 2026 | -1.588M |
| October 05, 2026 | -0.8235M |
| October 02, 2026 | -0.3958M |
| October 01, 2026 | -0.3958M |
| September 30, 2026 | -0.001M |
| September 29, 2026 | -0.9808M |
| September 28, 2026 | -0.6181M |
| September 25, 2026 | -0.6473M |
| September 24, 2026 | -0.4426M |
| September 23, 2026 | -0.4075M |
| September 22, 2026 | -0.232M |
| September 21, 2026 | -0.0448M |
| September 18, 2026 | -0.1969M |
| September 17, 2026 | -0.2788M |
| September 16, 2026 | -0.1033M |
| September 15, 2026 | 0.0956M |
| September 14, 2026 | 0.3179M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cerenome, Inc. | 4.075M |
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.941M |
| Total Expenses (Quarterly) | 2.941M |
| EPS Diluted (Quarterly) | -1.885 |
| Earnings Yield | -1.25K% |
| Normalized Earnings Yield | -1126.92 |